Clinical trials: CtDNA
Hepatocellular Carcinoma
Biomarker and Mechanism Study of Systemic Therapy in Unresectable HCC
The goal of this observational study is to evaluate the safety and efficacy of systemic therapies and identify predictive molecular biomarkers in patients with intermediate to advanced stage or unresectable hepatocellular…
- Trial name
- MUSE2 (NCT07786792)
- Testing
- Systemic therapy, Local therapy
- Volunteers
- 400 people
- Sponsor
- Shanghai Zhongshan Hospital
Colorectal Neoplasms Malignant, Minimal Residual Disease
Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II-III
This trial has been designed to prove the feasibility of using liquid biopsy detection of minimal residual disease (MRD) to guide the postsurgical clinical management of early colon cancer patients.
- Conditions
- Colorectal Neoplasms Malignant, Minimal Residual Disease, Circulating Tumor Cell
- Trial name
- NCT07821333
- Testing
- FOLFOXIRI, CAPOX
- Where
- 7 sites in Spain
- Volunteers
- 45 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Colorectal Cancer Metastatic
Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients
The goal of this clinical trial is to learn if the application of the chemotherapy FOLFIRI and cetuximab works better when given with scheduled breaks or continuously in adults with metastatic colorectal cancer.
- Trial name
- FIRE-11 (NCT07004413)
- Testing
- FOLFIRI+cetuximab, Guardant360 ctDNA assay
- Where
- Germany
- Volunteers
- 267 people
- Sponsor
- Charite University, Berlin, Germany
Diffuse Large B-Cell Lymphoma (DLBCL)
A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
Older patients with diffuse large B- cell lymphoma (DLBCL) do not have the same rates of disease control as younger patients and are at risk for toxicity.
- Trial name
- GOLD (NCT06828991)
- Testing
- Mosunetuzumab, ClonoSEQ
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Danielle Wallace
Neoplasms, Cancer
The Circulating Cell-free Genome Atlas Study
GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood.
- Trial name
- CCGA (NCT02889978)
- Where
- 140 sites in United States, Canada
- Volunteers
- 15,254 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Primary Mediastinal Large B-cell Lymphoma
Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)
The purpose of this study is to compare the predictive value in terms of specificity of circulating tumor DNA (ctDNA) and positron emission computed tomography (PET-CT) after 2 cycles of chemotherapy (C2), on the probability of…
- Trial name
- CAMIL (NCT04824950)
- Testing
- Circulating tumor DNA monitoring
- Where
- 2 sites in France
- Volunteers
- 87 people
- Sponsor
- Centre Henri Becquerel
Head and Neck Neoplasm, Carcinoma, Squamous Cell
Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma
Circulating tumor DNA (ctDNA) is a blood-based test that measures dying or dead cancer cells that are already circulating in the blood.
- Trial name
- NCT04099290
- Testing
- Blood and tumor samples
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Colorectal Liver Metastases (CRCLM), Unresectable Colorectal Liver Metastases
Yttrium-90 Radioembolization Neoadjuvant Therapy With Immune Marker Profiling and Dosimetry for Potentially Resectable Patients With Colorectal Liver Metastases
This is a observational, prospective, single arm, proof of concept study to assess safety, feasibility, and potential efficacy of combining Yttrium-90 transarterial radioembolization(TARE) with standard systemic therapy in…
- Trial name
- YRENE (NCT07406126)
- Testing
- Yttrium-90 Radioembolization with standard systemic therapy
- Where
- 5 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Fernando Gómez Muñoz
Colorectal Cancer, Peritoneal Metastases
A Prospective Multicentre Clinical Study of Dynamic Monitoring of Plasma ctDNA Methylation Markers to Predict Recurrence of Colorectal Cancer After Complete Resection of Peritoneal Metastases
The goal of this clinical trial is to explore the predictive effect of postoperative plasma ctDNA methylation status on postoperative recurrence free survival (RFS) of colorectal cancer patients with peritoneal metastasis after…
- Trial name
- NCT06903325
- Testing
- As an observational study, we did not intervene
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Colorectal Cancer
Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment
To investigate the efficacy of AMB-05X in patients with CRC with MRD as determined by a ctDNA(+) blood test and no clinically detectable radiographic disease.
- Trial name
- NCT06617858
- Testing
- AMB-05X
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
By doing this study, the research team would like to learn if using a blood test that measures the amount of tumor DNA in blood can help guide how to use chemotherapy combined with immunotherapy for individuals with head and neck…
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Neoplasms, Head Cancer
- Trial name
- NCT05420948
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Chicago
Stage II Colon Cancer, Stage III Colon Cancer
Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients
The aims of this study are to evaluate if an intensified adjuvant treatment with FOLFOXIRI could increase the rate of cases with undetectable ct-DNA after chemotherapy and to evaluate if a further adjuvant treatment with…
- Conditions
- Stage II Colon Cancer, Stage III Colon Cancer, HER2-positive Colon Cancer, RAS Wild-type Colon Cancer
- Trial name
- ERASE-CRC (NCT05062889)
- Testing
- 5-Fluorouracil continuous infusion FOLFOXIRI schedule, 5-Fluorouracil bolus FOLFOX schedule, 5-Fluorouracil continuous infusion FOLFOX schedule
- Where
- 28 sites in Italy
- Volunteers
- 477 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Colorectal Cancer
First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer
The CORRECT - MRD I study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for up to 5 years for recurrence.
- Trial name
- MRD (NCT06398743)
- Testing
- MRD
- Where
- 22 sites in Israel, Italy and 3 more
- Volunteers
- 416 people
- Sponsor
- Exact Sciences Corporation
Esophageal Squamous Cell Carcinoma (ESCC)
Multi-omics Monitoring of Dynamic Evolution in Esophageal Squamous Cell Carcinoma: PKU-ESCC-Monitor
This prospective observational study (PKU-ESCC-Monitor) aims to characterize the dynamic evolution of esophageal squamous cell carcinoma (ESCC) using integrated multi-omics, including tissue genomics, ctDNA, imaging features…
- Trial name
- PKU-ESCC (NCT07152535)
- Volunteers
- 255 people
- Sponsor
- Peking University Cancer Hospital & Institute
Colon Cancer, Colon Cancer (Stage II &Amp;Amp;Amp; III)
ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study
The goal of this clinical trial is to explore the disease-free survival period of elderly patients with high-risk stage II and stage III colon cancer based on ctDNA detection.
- Trial name
- ZJCH-CRCC-1 (NCT06609551)
- Testing
- 6-month adjuvant chemotherapy with 5-FU monotherapy, XELOX intensive treatment group
- Where
- China
- Volunteers
- 312 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer Metastatic, Breast Cancer Stage IV
Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy
After an initial screening phase to identify patients with persistent blood circulating DNA tumors, patients will be enrolled in the treatment phase that was designed as an open-label, multicentre, phase II study, to test the…
- Trial name
- SAFIR3LibHERty (NCT06680596)
- Testing
- trastuzumab derxutecan
- Where
- 40 sites in France
- Volunteers
- 80 people
- Sponsor
- UNICANCER
Non Small Cell Lung Cancer, Gastrointestinal Stromal Tumor (GIST)
Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients
ctDNA stands for circulating tumour DNA. As ctDNA is released by tumour cells into the blood stream, taking a blood sample and analysing it for ctDNA, can provide a lot of useful information about a patient's cancer.
- Conditions
- Non Small Cell Lung Cancer, Gastrointestinal Stromal Tumor (GIST), Colorectal Cancer, Biliary Tract Cancer
- Trial name
- CURTAIN (NCT07673861)
- Testing
- Marsden360 ctDNA test and GTAB review
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Diffuse Large B-Cell Lymphoma
MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma
This prospective feasibility study evaluates a minimal residual disease (MRD)-adapted treatment strategy in patients with diffuse large B-cell lymphoma (DLBCL) receiving frontline chemoimmunotherapy.
- Trial name
- NCT07517705
- Testing
- Low-Dose Radiation Therapy (LDRT), Standard Frontline Chemoimmunotherapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Nebraska
Preoperative and Postoperative ctDNA Comparison in Early Stage Lung Cnacer
Preoperative and Postoperative ctDNA Comparison in Early Stage Lung Cancer
Mutation-positive peripheral blood ctDNA became mutation-negative after surgical removal of the cancer tissue. All subjects in the control group were negative for ctDNA mutations。
- Trial name
- NCT03805256
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital of Soochow University
Non-small Cell Lung Cancer Stage III, Non-Small-Cell Lung Cancer Metastatic
T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure
The purpose of this study is to compare the frequency and abundance of T790M mutation among the different Clinical modes of EGFR-TKI failure.
- Trial name
- NCT02418234
- Testing
- mutation detection, ARMS and ddPCR, ctDNA analysis
- Where
- China
- Volunteers
- 314 people
- Sponsor
- First People's Hospital of Hangzhou